Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00930683 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma

A Phase 1 study of Scleroderma, sponsored by MedImmune.

Completed
Registry status
Phase 1
Development phase
34
Enrollment target
11
Study locations

NCT00930683 is a Phase 1 study of Scleroderma that has completed, run by MedImmune. The registered enrollment target is 34 participants, below the 401-participant average among 23 other Scleroderma trials with a reported enrollment target (92% lower). The trial reports 11 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00930683, a Phase 1 study of Scleroderma, has completed, sponsored by MedImmune.

COMPLETED
Registry status
Phase 1
Development phase
34 participants
Enrollment target
11
Study locations

Study Summary

To evaluate the safety and tolerability of a multiple-dosed drug (MEDI-546) in adults with scleroderma.

Conditions Studied

Scleroderma

Interventions

  • DRUG MEDI-546

Study Locations (11)

Texas

  • Metroplex Clinical Research Center - Dallas
  • Research Site - Houston

Utah

  • University of Utah Medical Center - Salt Lake City
  • Research Site - Salt Lake City

California

  • Research Site - Los Angeles

Massachusetts

  • Boston University - Boston

Michigan

  • Research Site - Ann Arbor

New Jersey

  • Research Site - New Brunswick

New York

  • Research Site - Lake Success

Ohio

  • Research Site - Toledo

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2009-09
Est. Completion 2011-07
Phase Phase 1

Sponsor

MedImmune

210 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00930683

The ClinicalTrials.gov registry entry for NCT00930683 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 401-participant average among 23 other Scleroderma trials with a reported enrollment target (92% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Scleroderma appearing as the primary indexed condition, and to 1 intervention - of which MEDI-546 is the first listed.

NCT00930683 reports 11 study locations spanning 9 distinct geographic areas - top geographies include Texas, Utah, California.

Frequently Asked Questions

What is clinical trial NCT00930683 about?

NCT00930683 is a clinical study titled "A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma". To evaluate the safety and tolerability of a multiple-dosed drug (MEDI-546) in adults with scleroderma.

What is the current status of trial NCT00930683?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2009-09. Estimated completion is 2011-07.

What conditions does trial NCT00930683 study?

This clinical trial studies the following conditions: Scleroderma.

What interventions are being tested in trial NCT00930683?

The interventions under investigation include: MEDI-546 (DRUG).

Who is sponsoring clinical trial NCT00930683?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00930683 being conducted?

This trial has 11 study locations across California, Massachusetts, Michigan, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Scleroderma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Scleroderma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.